Share prices for makers of insulin management devices got a bump today after Medtronic (NYSE:MDT) reported today that supply problems pushed sales down -1% for its diabetes division.
The Fridley, Minn.-based company, which released its fiscal 2018 first-quarter results this morning, posted diabetes revenues of $499 million for the three months ended July 28. The decline was driven by strong demand for Medtronic’s CGM-enabled insulin pumps, especially the MiniMed 670G hybrid closed-loop device.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic supply woes buoy insulin device makers appeared first on MassDevice.
from MassDevice http://ift.tt/2wkKNls
Cap comentari:
Publica un comentari a l'entrada